MET Alterations in Lung Cancer
MET alterations are most common in lung cancer, but they also occur in several other cancer types. In some cases of lung cancer, specifically non-small cell lung cancer, the MET gene amplification can cause the cancerous cells to reproduce and spread more quickly than lung cancer cases without known biomarkers. Those who test positive for a MET amplification may respond better to a MET targeted therapy, than other standard treatments.
MET Crusaders Cancer Patient and Caregiver Support Group created a resourceful newsletter including information on the latest therapies for lung cancer and MET alterations. The newsletter lists and details new clinical trial therapies such as:
- Telisotuzumab vedotin
- S49076, gefitinib
MET Crusaders Cancer Patient and Caregiver Support Group was founded in 2019 by MET lung cancer survivor John Hallick, when he was seeking ways to help others with MET altered cancer and wanted to promote new treatments. Today, MET Crusaders is a community dedicated to helping lung cancer patients with MET alterations live normal lives. You can download and read the full Crusader Newsletter below.
Lung Cancer With MET Alteration Clinical Trials
Non-small Cell Lung Cancer (NSCLC) clinical trials for patients with MET alterations have shown improved outcomes with targeted therapy and immunotherapy drugs. There are over 60 lung cancer MET-amplified clinical trials available to eligible patients. Download and read the full newsletter for more on clinical trials and therapies targeting MET alterations in lung cancer. There is also more information about these trials and lung cancer with MET alterations on the MET Crusaders website and Facebook group.